Intellia Thera CS (NTLA)

$11.74 +0.31 (2.71%)
Market Cap 1.32B
Revenue (ttm) 57.88M
Net Income (ttm) -519.02M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -896.72%
Debt to Equity Ratio 0.00
Volume 7,921,600
Avg Vol 5,599,640
Day's Range N/A - N/A
Shares Out 115.83M
Stochastic %K 83%
Beta 2.05
Analysts Sell
Price Target $21.98

Company Profile

Intellia Therapeutics, Inc., a clinical-stage gene editing company, focuses on the development of curative genome editing treatments. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 that is in Phase 1/2 study for the treatment of hereditary angioedema. It also focusses on the research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune dis...

Industry: Biotechnology
Sector: Healthcare
Phone: 857 285 6200
Address:
40 Erie Street, Suite 130, Cambridge, United States
SteveWiersteiner414
SteveWiersteiner414 Jan. 14 at 5:34 AM
$BA $NTLA Industrial meets biotech innovation
0 · Reply
3DBuilds
3DBuilds Jan. 14 at 4:54 AM
$NTLA
0 · Reply
quark_n_jaguar
quark_n_jaguar Jan. 14 at 4:04 AM
$NTLA would be good if Intellia releases more data or autopsy results of the fatality. Using Gemini - Sepsis-induced liver injury (SILI) typically presents with a marked predominance of AST over ALT. An AST/ALT ratio ≥ 1.84 is a strong prognostic marker for 28-day mortality in septic shock patients. Classical drug-induced liver injury (DILI) usually results in a predominance of ALT over AST. In previous asymptomatic cases in Intellia's trial, ALT peaked higher and resolved more slowly than AST. Liver Histology: A biopsy can reveal specific patterns of damage. Centrilobular necrosis is common in shock/sepsis, while portal inflammation or an infiltrate of specific immune cells (T-cells/eosinophils) would point more strongly toward a drug-induced immune reaction Systemic Evidence: Pathologists look for ICAM-1 upregulation or evidence of hemophagocytosis, which are markers that can help confirm or exclude sepsis as the primary driver of organ failure.
0 · Reply
dayfader47
dayfader47 Jan. 14 at 3:14 AM
$NTLA I wouldn’t be surprised if there is some near term resistance. People who bought after the first crash then got stuck after the second one. Consolidation. If institutions start to change their positions though we might blow right through it.
0 · Reply
jeojackson
jeojackson Jan. 14 at 1:41 AM
$NTLA Hope it does a BEAM tomorrow (20%).
0 · Reply
UgoGreg
UgoGreg Jan. 13 at 10:15 PM
$NTLA https://youtu.be/pXFO9_cJJUM
0 · Reply
APman
APman Jan. 13 at 8:58 PM
$NTLA Picked up another [email protected] Threw the dice!
0 · Reply
StockWookie
StockWookie Jan. 13 at 8:58 PM
$NTLA Do not be tricked this is not a sell the news event ….. These shorts are digging deeper lol
1 · Reply
Picklez_
Picklez_ Jan. 13 at 8:23 PM
$NTLA we gonna do 6.75mil again algos?
0 · Reply
Unicorn2020
Unicorn2020 Jan. 13 at 7:40 PM
$NTLA Any good news comes out at JPM will quickly send the stock to $16 at least possible $28 if too good.
0 · Reply
Latest News on NTLA
Intellia Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Jan 7, 2026, 7:30 AM EST - 6 days ago

Intellia Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dec 5, 2025, 4:01 PM EST - 5 weeks ago

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

The Short List — Top 10 Most Shorted Stocks Right Now

Nov 26, 2025, 11:34 AM EST - 6 weeks ago

The Short List — Top 10 Most Shorted Stocks Right Now

ATYR CMBM HIMS HTZ LCID REPL SOC

Intellia Therapeutics Presents Positive Longer-Term Phase 1 Data of Nexiguran Ziclumeran (nex-z) in Patients with Transthyretin (ATTR) Amyloidosis with Cardiomyopathy

Nov 10, 2025, 3:17 PM EST - 2 months ago

Intellia Therapeutics Presents Positive Longer-Term Phase 1 Data of Nexiguran Ziclumeran (nex-z) in Patients with Transthyretin (ATTR) Amyloidosis with Cardiomyopathy

Intellia Therapeutics Presents Positive Pooled Phase 1/2 Data of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema

Nov 8, 2025, 5:13 PM EST - 2 months ago

Intellia Therapeutics Presents Positive Pooled Phase 1/2 Data of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema

Intellia Therapeutics, Inc. (NTLA) Q3 2025 Earnings Call Transcript

Nov 7, 2025, 5:46 AM EST - 2 months ago

Intellia Therapeutics, Inc. (NTLA) Q3 2025 Earnings Call Transcript

US FDA places clinical hold on Intellia's two gene-editing treatment trials

Oct 29, 2025, 5:11 PM EDT - 2 months ago

US FDA places clinical hold on Intellia's two gene-editing treatment trials

Intellia Therapeutics, Inc. (NTLA) Discusses Safety Event and Protocol Pause in MAGNITUDE Clinical Trials of Nex-Z Transcript

Oct 27, 2025, 11:17 AM EDT - 2 months ago

Intellia Therapeutics, Inc. (NTLA) Discusses Safety Event and Protocol Pause in MAGNITUDE Clinical Trials of Nex-Z Transcript

Intellia pauses late-stage trials of gene-editing treatment after serious liver event

Oct 27, 2025, 7:38 AM EDT - 2 months ago

Intellia pauses late-stage trials of gene-editing treatment after serious liver event

Intellia Therapeutics Provides Update on MAGNITUDE Clinical Trials of Nexiguran Ziclumeran (nex-z)

Oct 27, 2025, 7:30 AM EDT - 2 months ago

Intellia Therapeutics Provides Update on MAGNITUDE Clinical Trials of Nexiguran Ziclumeran (nex-z)

Crispr And Intellia: Advancing In Vivo Gene Editing As 2025 Results Strengthen Investment Outlook

Oct 24, 2025, 8:15 AM EDT - 2 months ago

Crispr And Intellia: Advancing In Vivo Gene Editing As 2025 Results Strengthen Investment Outlook

Intellia Highlights Clinical Improvements With One-Time Dose Of Experimental Drug

Sep 25, 2025, 1:57 PM EDT - 3 months ago

Intellia Highlights Clinical Improvements With One-Time Dose Of Experimental Drug

Intellia Therapeutics Announces Positive Longer-Term Phase 1 Data for Nexiguran Ziclumeran (nex-z) in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy

Sep 25, 2025, 9:52 AM EDT - 3 months ago

Intellia Therapeutics Announces Positive Longer-Term Phase 1 Data for Nexiguran Ziclumeran (nex-z) in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy

Intellia Therapeutics: Full Trial Enrollment Wows Market - Underlines Buy Thesis

Sep 19, 2025, 2:31 PM EDT - 4 months ago

Intellia Therapeutics: Full Trial Enrollment Wows Market - Underlines Buy Thesis

Intellia Therapeutics Completes Enrollment in the Global Phase 3 HAELO Study of Lonvoguran Ziclumeran (lonvo-z) for Hereditary Angioedema

Sep 18, 2025, 7:30 AM EDT - 4 months ago

Intellia Therapeutics Completes Enrollment in the Global Phase 3 HAELO Study of Lonvoguran Ziclumeran (lonvo-z) for Hereditary Angioedema

Why big players are pouring millions in THIS biotech stock

Sep 1, 2025, 8:43 AM EDT - 4 months ago

Why big players are pouring millions in THIS biotech stock

Intellia Therapeutics: It May Be Time To Get Excited And Buy (Upgrade)

Aug 15, 2025, 12:24 PM EDT - 5 months ago

Intellia Therapeutics: It May Be Time To Get Excited And Buy (Upgrade)

Intellia Therapeutics, Inc. (NTLA) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 8:17 PM EDT - 5 months ago

Intellia Therapeutics, Inc. (NTLA) Q2 2025 Earnings Call Transcript

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Aug 1, 2025, 7:30 AM EDT - 5 months ago

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2025 Earnings and Company Updates

Jul 31, 2025, 7:30 AM EDT - 5 months ago

Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2025 Earnings and Company Updates

What's Going On With Sarepta, Capricor And Other Gene Therapy Stocks On Wednesday?

Jul 30, 2025, 11:07 AM EDT - 5 months ago

What's Going On With Sarepta, Capricor And Other Gene Therapy Stocks On Wednesday?

CAPR SRPT CABA NGNE QURE RCKT

With Intellia Therapeutics, Human Patience Beat Hot-Take Trading: Still At 'Buy'

Jul 18, 2025, 8:00 AM EDT - 6 months ago

With Intellia Therapeutics, Human Patience Beat Hot-Take Trading: Still At 'Buy'

Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy of Allergy and Clinical Immunology Congress

Jun 15, 2025, 10:45 AM EDT - 7 months ago

Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy of Allergy and Clinical Immunology Congress

Intellia Therapeutics' Rare Heart Disease Candidate Reports Liver Enzyme Spike In Phase 3 Trial, But Stays On Course

May 29, 2025, 11:25 AM EDT - 8 months ago

Intellia Therapeutics' Rare Heart Disease Candidate Reports Liver Enzyme Spike In Phase 3 Trial, But Stays On Course

I Missed The Quantum Rally - I Won't Miss The Next One

May 20, 2025, 5:47 AM EDT - 8 months ago

I Missed The Quantum Rally - I Won't Miss The Next One

AMSC AUTL CAPR CLPT EDIT VANI VERV

Intellia Announces Positive Two-Year Follow-Up Data from Ongoing Phase 1 Study of Nexiguran Ziclumeran (nex-z), in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy at Peripheral Nerve Society Annual Meeting

May 18, 2025, 7:25 AM EDT - 8 months ago

Intellia Announces Positive Two-Year Follow-Up Data from Ongoing Phase 1 Study of Nexiguran Ziclumeran (nex-z), in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy at Peripheral Nerve Society Annual Meeting

Intellia Therapeutics, Inc. (NTLA) BofA Securities 2025 Healthcare Conference (Transcript)

May 14, 2025, 1:57 PM EDT - 8 months ago

Intellia Therapeutics, Inc. (NTLA) BofA Securities 2025 Healthcare Conference (Transcript)

Intellia Therapeutics Shares Have Struggled, But It's Now Go-Time (Rating Upgrade)

May 12, 2025, 9:07 AM EDT - 8 months ago

Intellia Therapeutics Shares Have Struggled, But It's Now Go-Time (Rating Upgrade)

Intellia Therapeutics, Inc. (NTLA) Q1 2025 Earnings Call Transcript

May 8, 2025, 11:37 AM EDT - 8 months ago

Intellia Therapeutics, Inc. (NTLA) Q1 2025 Earnings Call Transcript

CRISPR Therapeutics And Intellia Therapeutics: Balancing Market Uncertainty Against Pipeline Catalysts

May 5, 2025, 4:44 AM EDT - 9 months ago

CRISPR Therapeutics And Intellia Therapeutics: Balancing Market Uncertainty Against Pipeline Catalysts

CRSP

Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2025 Earnings and Company Updates

May 1, 2025, 7:30 AM EDT - 9 months ago

Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2025 Earnings and Company Updates

Lawsuit for Investors in shares of Intellia Therapeutics, Inc. (NASDAQ: NTLA) announced by the Shareholders Foundation

Apr 23, 2025, 9:50 AM EDT - 9 months ago

Lawsuit for Investors in shares of Intellia Therapeutics, Inc. (NASDAQ: NTLA) announced by the Shareholders Foundation

Final Deadline Today for the Intellia Therapeutics, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - NTLA

Apr 14, 2025, 10:58 AM EDT - 9 months ago

Final Deadline Today for the Intellia Therapeutics, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - NTLA

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Intellia Therapeutics

Apr 10, 2025, 10:40 AM EDT - 9 months ago

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Intellia Therapeutics

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Intellia Therapeutics

Apr 9, 2025, 10:49 AM EDT - 9 months ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Intellia Therapeutics

SteveWiersteiner414
SteveWiersteiner414 Jan. 14 at 5:34 AM
$BA $NTLA Industrial meets biotech innovation
0 · Reply
3DBuilds
3DBuilds Jan. 14 at 4:54 AM
$NTLA
0 · Reply
quark_n_jaguar
quark_n_jaguar Jan. 14 at 4:04 AM
$NTLA would be good if Intellia releases more data or autopsy results of the fatality. Using Gemini - Sepsis-induced liver injury (SILI) typically presents with a marked predominance of AST over ALT. An AST/ALT ratio ≥ 1.84 is a strong prognostic marker for 28-day mortality in septic shock patients. Classical drug-induced liver injury (DILI) usually results in a predominance of ALT over AST. In previous asymptomatic cases in Intellia's trial, ALT peaked higher and resolved more slowly than AST. Liver Histology: A biopsy can reveal specific patterns of damage. Centrilobular necrosis is common in shock/sepsis, while portal inflammation or an infiltrate of specific immune cells (T-cells/eosinophils) would point more strongly toward a drug-induced immune reaction Systemic Evidence: Pathologists look for ICAM-1 upregulation or evidence of hemophagocytosis, which are markers that can help confirm or exclude sepsis as the primary driver of organ failure.
0 · Reply
dayfader47
dayfader47 Jan. 14 at 3:14 AM
$NTLA I wouldn’t be surprised if there is some near term resistance. People who bought after the first crash then got stuck after the second one. Consolidation. If institutions start to change their positions though we might blow right through it.
0 · Reply
jeojackson
jeojackson Jan. 14 at 1:41 AM
$NTLA Hope it does a BEAM tomorrow (20%).
0 · Reply
UgoGreg
UgoGreg Jan. 13 at 10:15 PM
$NTLA https://youtu.be/pXFO9_cJJUM
0 · Reply
APman
APman Jan. 13 at 8:58 PM
$NTLA Picked up another [email protected] Threw the dice!
0 · Reply
StockWookie
StockWookie Jan. 13 at 8:58 PM
$NTLA Do not be tricked this is not a sell the news event ….. These shorts are digging deeper lol
1 · Reply
Picklez_
Picklez_ Jan. 13 at 8:23 PM
$NTLA we gonna do 6.75mil again algos?
0 · Reply
Unicorn2020
Unicorn2020 Jan. 13 at 7:40 PM
$NTLA Any good news comes out at JPM will quickly send the stock to $16 at least possible $28 if too good.
0 · Reply
spacecity777
spacecity777 Jan. 13 at 7:01 PM
$NTLA once the halt is lifted the stock will gain even more momentum. The recent downgrades and lowered price targets will be set back, one after the other. The recent purchases by Cohen and Wood are a very clear indicator good things are coming for longs who have a little patience. I wouldn't be surprised to trade up to or past $17 by the end of February, if not sooner.
1 · Reply
RAvanBeek91
RAvanBeek91 Jan. 13 at 6:57 PM
$NTLA
0 · Reply
StockWookie
StockWookie Jan. 13 at 6:49 PM
$NTLA It will squuuuuuuezzzzze all afternoon and morning !!!!!!
0 · Reply
Waxi123
Waxi123 Jan. 13 at 6:40 PM
$NTLA the company will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 14, 2026 at 9:00 a.m.
1 · Reply
PSDL75
PSDL75 Jan. 13 at 5:26 PM
$NTLA carry on
0 · Reply
Cutlass
Cutlass Jan. 13 at 5:13 PM
$NTLA 🍒
0 · Reply
geniuscali
geniuscali Jan. 13 at 4:39 PM
$NTLA wouldnt it beutiful if some whale decided to do some true major buys and trugger a true MOAB short squeeze
1 · Reply
TheWolfOfWaterdown
TheWolfOfWaterdown Jan. 13 at 4:20 PM
$NTLA 3 million volume already, panic covering before tomorrow JPM
0 · Reply
hichemben
hichemben Jan. 13 at 4:08 PM
$NTLA Big short squeeze incoming with hold lift +100% 🚀💎 Top 5 shorted stock in BioTech🔥 "Cathie Wood’s ARK ETF published their daily trades for Tuesday, January 13, 2026, showcasing continued strategic moves in the biotechnology and industrial sectors. The largest dollar-value trade was the purchase of 216,411 shares of Intellia Therapeutics Inc (NASDAQ:NTLA) across its ARKK and ARKG ETFs, amounting to $2,473,577. This marks a consistent pattern of investment in Intellia, as ARK has been accumulating shares of the gene-editing company over recent days"
0 · Reply
GoFrogs09
GoFrogs09 Jan. 13 at 4:00 PM
$NTLA beast mode!
0 · Reply
StockWookie
StockWookie Jan. 13 at 3:59 PM
$NTLA Please Natalia ! Natalia ! I will go first !
0 · Reply
APman
APman Jan. 13 at 3:49 PM
$NTLA NTLA 15 squeeze!
0 · Reply